5.2.7.3	  Alpha 1-blockers + beta-3 agonist  Mechanism of action: Combination therapy consists of an α1-blocker (Section 5.2.1) together with a beta-3-  agonist (Section 5.2.4) as an add-on therapy in males receiving α1-blockers with persisting OAB symptoms.,
Summary of evidence,LE
Combination treatment with α1-blockers and mirabegron results in a slight decrease of number of   voids and urgency episodes per day compared with α1-blockers alone.,1b
Adverse events of both drug classes are seen with combined treatment using α1-blockers and   mirabegron.,1b
